Revue De Medecine Interne最新文献

L’hyperparathyroïdie primaire : du diagnostic à la prise en charge thérapeutique [原发性甲状旁腺功能亢进症：从诊断到治疗]。

IF 0.7 4区医学

Revue De Medecine Interne Pub Date : 2025-04-01 DOI: 10.1016/j.revmed.2024.07.004

Laure Carpentier , Benjamin Bouillet

{"title":"L’hyperparathyroïdie primaire : du diagnostic à la prise en charge thérapeutique","authors":"Laure Carpentier , Benjamin Bouillet","doi":"10.1016/j.revmed.2024.07.004","DOIUrl":"10.1016/j.revmed.2024.07.004","url":null,"abstract":"<div><div>Primary hyperparathyroidism (PHPT) is the leading cause of hypercalcemia. It is secondary to hypersecretion of parathyroid hormone (PTH) by the parathyroid glands. Today, PHTP is asymptomatic in 80–90% of cases. Its repercussions are mainly renal (nephrolithiasis, nephrocalcinosis, decline in renal function) and skeletal (osteoporosis, fractures), and should be systematically investigated. Diagnosis is only biological, and in its classic form relies on the association of hypercalcemia, inappropriate PTH (normal or elevated) and hypercalciuria. Diagnosis of normocalcemic forms, where only PTH is elevated, requires elimination of secondary hyperparathyroidism and confirmation of elevated PTH on two consecutive samples, over a 3 to 6 months period. Imaging evaluation, which combines neck ultrasound with scintigraphy or <sup>18</sup>F-choline PET/CT, is of interest only if surgery is indicated. Surgical management of the hyperfunctioning parathyroid gland(s) is the only curative treatment for HPTP. Medical management concerns patients for whom surgery is not indicated, who present a surgical contraindication or who refuse surgery. The diagnosis of HPTP warrants contact with an endocrinologist to ensure its management.</div></div>","PeriodicalId":54458,"journal":{"name":"Revue De Medecine Interne","volume":"46 4","pages":"Pages 204-210"},"PeriodicalIF":0.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142157068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Issue Contents

IF 0.7 4区医学

Revue De Medecine Interne Pub Date : 2025-04-01 DOI: 10.1016/S0248-8663(25)00517-X

引用次数: 0

Prise en charge de l’encéphalopathie hépatique : revue générale [肝性脑病的治疗：综述]。

IF 0.7 4区医学

Revue De Medecine Interne Pub Date : 2025-04-01 DOI: 10.1016/j.revmed.2024.10.007

Florent Broca , Mylène Dufrenoy , Mickaël Martin

引用次数: 0

L’hématopoïèse extramédullaire, une complication rare de la drépanocytose : à propos de six cas et revue de la littérature 髓外造血，镰状细胞病的罕见并发症：六例系列分析和文献复习。

IF 0.7 4区医学

Revue De Medecine Interne Pub Date : 2025-04-01 DOI: 10.1016/j.revmed.2024.12.006

Ugo Boccadifuoco , Geoffrey Cheminet , Benjamin Morino , Jean-Benoît Arlet

{"title":"L’hématopoïèse extramédullaire, une complication rare de la drépanocytose : à propos de six cas et revue de la littérature","authors":"Ugo Boccadifuoco , Geoffrey Cheminet , Benjamin Morino , Jean-Benoît Arlet","doi":"10.1016/j.revmed.2024.12.006","DOIUrl":"10.1016/j.revmed.2024.12.006","url":null,"abstract":"<div><h3>Introduction</h3><div>Extramedullary hematopoiesis (EMH) is very rarely described during sickle cell disease (SCD). Our aim was to describe six cases of EMH occurring in adult SCD patients and to conduct a literature review.</div></div><div><h3>Methods</h3><div>Retrospective, descriptive, and monocentric study, identifying all cases of EMH recorded in our cohort of adult SCD patients, up to April 2024. A literature review via PubMed included thirty-five articles (44 patients).</div></div><div><h3>Results</h3><div>Six patients (4 men, 83.3% with SS genotype [<em>n</em>  =3), peri-articular in the hip (<em>n</em>  =1), hepatic (<em>n</em>  =1) and was similar to the localizations reported in the literature. EMH was symptomatic at diagnosis in half of the cases. The diagnosis was established by histology (<em>n</em>  =4/4). The median baseline hemoglobin was 9.1 (extremes 5.8–10.9) g/dL. A watch-and-wait approach was primarily observed.</div></div><div><h3>Conclusion</h3><div>EMH in SCD patients appears to be rare, with varied localizations. Its diagnosis is made with MRI and/or biopsy, and its treatment is not consensual.</div></div>","PeriodicalId":54458,"journal":{"name":"Revue De Medecine Interne","volume":"46 4","pages":"Pages 193-203"},"PeriodicalIF":0.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ostéoporose : pourquoi quand et avec quel(s) médicament(s) traiter ? Comment la prévenir ?

IF 0.7 4区医学

Revue De Medecine Interne Pub Date : 2025-04-01 DOI: 10.1016/j.revmed.2025.04.001

Rakiba Belkhir

引用次数: 0

Aedes albopictus (moustique tigre) et arboviroses : à quoi s’attendre dans les années à venir ?

IF 0.7 4区医学

Revue De Medecine Interne Pub Date : 2025-04-01 DOI: 10.1016/j.revmed.2025.02.005

Camille Bonnet, Daouda Niaré, Marion Debin, Thierry Blanchon

引用次数: 0

Dr Françoise Badet, cheffe du service de médecine interne, rhumatologie, infectiologie et hématologie au CH de Vienne, présidente de l’association Huma’Vienne

IF 0.7 4区医学

Revue De Medecine Interne Pub Date : 2025-04-01 DOI: 10.1016/j.revmed.2025.02.006

Jonathan Sormani , Aïcha Kante , Anaïs Roeser

引用次数: 0

Utilisation de l’hydroxychloroquine dans les pathologies obstétricales récurrentes à médiation immune (en dehors du lupus systémique) : fondements et preuves scientifiques [羟氯喹在复发性免疫介导的产科疾病（系统性狼疮除外）中的应用：科学依据和证据]。

IF 0.7 4区医学

Revue De Medecine Interne Pub Date : 2025-04-01 DOI: 10.1016/j.revmed.2024.12.004

Amandine Dernoncourt , Valéry Salle , Meryam Cheloufi , Gilles Kayem , Arsène Mekinian

{"title":"Utilisation de l’hydroxychloroquine dans les pathologies obstétricales récurrentes à médiation immune (en dehors du lupus systémique) : fondements et preuves scientifiques","authors":"Amandine Dernoncourt , Valéry Salle , Meryam Cheloufi , Gilles Kayem , Arsène Mekinian","doi":"10.1016/j.revmed.2024.12.004","DOIUrl":"10.1016/j.revmed.2024.12.004","url":null,"abstract":"<div><div>Hydroxychloroquine (HCQ), a synthetic antimalarial, is recognized for its immunomodulatory, anti-inflammatory and vascular-protective effects. In 20–30% of cases of primary obstetrical antiphospholipid syndrome (APS), the combination of antiplatelet aggregation and prophylactic anticoagulation fails to prevent obstetrical complications, a situation referred to as refractory obstetrical APS. This is partly due to the pro-inflammatory effects of antiphospholipid antibodies (aPL) binding to decidual and trophoblastic cells, which compromise embryonic implantation and placentation. Experimental studies in vitro and in mouse models have shown that HCQ can inhibit the detrimental effect of aPLs on trophoblastic invasion, findings corroborated by retrospective observational clinical studies. However, no randomized controlled trial has evaluated the addition of HCQ to conventional therapy for refractory obstetric APS. The hypothesis of allo-immune and/or autoimmune mechanisms involved in cases of recurrent pregnancy loss (RPL) with no identified cause and in chronic intervillositis of unknown etiology (CIUE) has led to the empirical use of HCQ in these indications. However, current evidence does not support its use in unexplained RPL. A few clinical studies of low scientific evidence suggest a benefit of HCQ in CIUE, but further data are needed. Finally, pre-eclampsia (PE) is another pregnancy-related condition at risk of recurrence, and its pathogenesis also seems to involve an imbalance in immune responses. HCQ's antioxidant properties could have a positive effect on endothelial dysfunction, a key component of PE.</div></div>","PeriodicalId":54458,"journal":{"name":"Revue De Medecine Interne","volume":"46 4","pages":"Pages 220-228"},"PeriodicalIF":0.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Purpura thrombopénique immunologique réfractaire révélant un syndrome MYH9 chez un homme de 64 ans

IF 0.7 4区医学

Revue De Medecine Interne Pub Date : 2025-04-01 DOI: 10.1016/j.revmed.2024.12.005

Quentin Bodard , Guillaume Fredon , Agnès Riche , Xavier Tessier , Johanne Liberatore

引用次数: 0

Un érythème fébrile récidivant

IF 0.7 4区医学

Revue De Medecine Interne Pub Date : 2025-04-01 DOI: 10.1016/j.revmed.2024.12.008

Brigitte Granel, Quentin Gomes De Pinho, Audrey Benyamine, Pascal Rossi

引用次数: 0